82. Novel Clinical Risks for Fungal Disease
Thursday, October 4, 2018: 2:00 PM-3:15 PM
Room: W 2014-2016
Co-organized with the National Institute of Allergy and Infectious Diseases

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • evaluate clinical risk for fungal disease with small molecule kinase inhibitors
  • discuss the clinical risk for fungal disease with chimeric antigen receptor T cell therapy
  • discuss fungal prophylaxis in high-risk groups
  • explain the epidemiology of invasive fungal infections

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Members-in-training, Microbiologists, Pharmacists, Researchers, Scientists

Tracks: Transplant ID, Trainee, Investigative ID, Pediatric ID, Epidemiology and Infection Control, Adult ID

Moderators:  Jeniel Nett, MD, PhD, University of Wisconsin, Madison and Joshua Nosanchuk, MD, FIDSA, Albert Einstein College of Medicine

2:00 PM
What's Brewing with Ibrutinib?
Gil Redelman-Sidi, MD

2:25 PM
Small Molecules, Big Trouble
Michail Lionakis, M.D., Sc.D.

2:50 PM

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-209-L01-P


J. Nett, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.